版本:
中国

BRIEF-TG Therapeutics posts qtrly loss per share of $0.52

May 5 TG Therapeutics Inc:

* TG Therapeutics Inc provides business update and reports first quarter 2017 financial results

* Qtrly license revenue $38,095 versus $38,095

* Cash, cash equivalents, investment securities, interest receivable $109.5 million as of March 31 to be sufficient to fund planned operations through 2018

* Qtrly loss per share $0.52

* Cash, cash equivalents, investment securities, and interest receivable will be sufficient to fund planned operations through 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐